title: Cardiotoxicity from anthracycline and cardioprotection in paediatric cancer patients.
abstract: Notwithstanding the steady progress in survival rates of children and adolescents suffering from cancer, the benefits associated with chemotherapy do not come without risks involving multiple organs and systems, including the cardiovascular apparatus. Anthracyclines-often administered in combination with radiation therapy and/or surgery-are the most used chemotherapeutic compounds in order to treat tumours and blood malignancies even in paediatric age. Being an important side-effect of anthracyclines, carduitoxicity may limit their efficacy during the treatment and induce long-term sequelae, observed even many years after therapy completion. The purpose of this review was to perform an overview about all the possible strategies to prevent and/or limit the anthracyclines adverse side-effects for the cardiovascular system in childhood cancer survivors.
authors.affiliation: aDepartment of Medical Sciences 'Mario Aresu', University of Cagliari bGeneral Surgery and Medical-Surgery Specialities Department, University of Catania cDivision of Cardiology, Istituto Nazionale per lo Studio e la Cura dei Tumori 'Fondazione Giovanni Pascale'-IRCCS, Naples, Italy.
authors.forename: Pier P
authors.initials: PP
authors.lastname: Bassareo
authors.forename: Ines
authors.initials: I
authors.lastname: Monte
authors.forename: Claudia
authors.initials: C
authors.lastname: Romano
authors.forename: Martino
authors.initials: M
authors.lastname: Deidda
authors.forename: Alessandra
authors.initials: A
authors.lastname: Piras
authors.forename: Lucia
authors.initials: L
authors.lastname: Cugusi
authors.forename: Carmela
authors.initials: C
authors.lastname: Coppola
authors.forename: Francesca
authors.initials: F
authors.lastname: Galletta
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Mercuro
mesh_terms: D000293:Adolescent; D018943:Anthracyclines / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D015415:Biomarkers; D066126:Cardiotoxicity / Q000503:physiopathology; D002648:Child; D004452:Echocardiography; D006321:Heart / Q000187:drug effects / Q000503:physiopathology; D006333:Heart Failure / Q000139:chemically induced* / Q000503:physiopathology / Q000517:prevention & control*; D006801:Humans; D008991:Monitoring, Physiologic; D009369:Neoplasms / Q000188:drug therapy
chemical_list: D018943:Anthracyclines; D000970:Antineoplastic Agents; D015415:Biomarkers